Enovis Corporation (NYSE:ENOV) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its stake in Enovis Corporation (NYSE:ENOV - Free Report) by 71.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,280 shares of the company's stock after selling 21,236 shares during the quarter. Mutual of America Capital Management LLC's holdings in Enovis were worth $316,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in ENOV. Quadrant Capital Group LLC lifted its position in Enovis by 53.0% in the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock valued at $30,000 after acquiring an additional 239 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of Enovis by 0.7% in the 4th quarter. California State Teachers Retirement System now owns 52,236 shares of the company's stock worth $2,292,000 after purchasing an additional 350 shares in the last quarter. Xponance Inc. increased its stake in Enovis by 7.8% in the 4th quarter. Xponance Inc. now owns 6,380 shares of the company's stock worth $280,000 after buying an additional 462 shares in the last quarter. Farther Finance Advisors LLC increased its stake in Enovis by 266.7% in the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after buying an additional 536 shares in the last quarter. Finally, Treasurer of the State of North Carolina boosted its holdings in shares of Enovis by 2.5% during the 4th quarter. Treasurer of the State of North Carolina now owns 24,347 shares of the company's stock valued at $1,068,000 after purchasing an additional 590 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on ENOV. Canaccord Genuity Group lowered their price target on shares of Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Evercore ISI lowered their price target on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. JMP Securities decreased their price objective on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Finally, Needham & Company LLC decreased their price objective on shares of Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $55.60.

Enovis Stock Performance

Shares of ENOV traded up $0.37 during trading hours on Friday, reaching $27.53. 1,126,050 shares of the company traded hands, compared to its average volume of 1,191,792. The stock has a market capitalization of $1.57 billion, a P/E ratio of -1.97 and a beta of 1.70. The business has a fifty day moving average price of $31.86 and a 200-day moving average price of $36.73. Enovis Corporation has a 12-month low of $25.93 and a 12-month high of $49.83. The company has a quick ratio of 1.32, a current ratio of 2.55 and a debt-to-equity ratio of 0.52.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. The company had revenue of $558.83 million during the quarter, compared to the consensus estimate of $558.80 million. Enovis had a negative net margin of 37.65% and a positive return on equity of 5.99%. The firm's quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.50 earnings per share. Equities analysts anticipate that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.